BTF granted US patent for 'Bioballs'
Thursday, 23 September, 2004
Private Sydney-based biotech BTF has been granted a US patent for its BioBall quality-control product.
The patent protects its BioBall technology, which uses a flow cytometer to count out precisely 30 viable bacteria. The bacteria are freeze dried in a drop of nutrient fluid as a 'Bioball' pellet.
The pellets can be reconstituted and used as a control, eliminating the need for labs to perform routine serial dilutions.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
